A candidate gene approach to ANCA-associated vasculitis reveals links to the C3 and CTLA-4 genes but not to the IL1-Ra and Fcγ-RIIa genes

Kidney and Blood Pressure Research

Volumn 37, Issue 6, 2013, Pages 641-648

  Persson, Ulf ^a,b   Gullstrand, Birgitta ^a   Pettersson, Åsa ^a   Sturfelt, Gunnar ^a   Truedsson, Lennart ^a   Segelmark, Mårten ^a,c,d  

^a LUND UNIVERSITY   (Sweden)

^b Capio AB   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d Department of Clinical Immunology and Transfusion Medicine   (Sweden)

Author keywords

ANCA; Genetics; Granulomatosis with polyangiitis; Microscopic polyangiitis; Wegener's granulomatosis

Indexed keywords

COMPLEMENT COMPONENT C3; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FC RECEPTOR IIA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MYELOBLASTIN; MYELOPEROXIDASE;

ALLELE; ANCA ASSOCIATED VASCULITIS; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ASSOCIATION; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; UNTRANSLATED REGION; WEGENER GRANULOMATOSIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; COHORT STUDIES; COMPLEMENT C3; CTLA-4 ANTIGEN; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC LINKAGE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; PROSPECTIVE STUDIES; RECEPTORS, IGG; RETROSPECTIVE STUDIES;

EID: 84891084587     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000355744     Document Type: Article

References (36)

1. Rarok AA, Limburg PC, Kallenberg CG. Neutrophil-Activating potential of antineutrophil cytoplasm autoantibodies. J Leukoc Biol 2003; 74: 3-15
2. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007; 170: 52-64
3. Franchi L, Eigenbrod T, Nunez G. Cutting edge: TNF-Alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol 2009; 183: 792-796
4. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12-17
5. Pendergraft WF, 3rd, Preston GA, Shah RR, Tropsha A, Carter CW, Jr., Jennette JC, Falk RJ. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004; 10: 72-79
6. Kain R, Exner M, Brandes R, Ziebermayr R, Cunningham D, Alderson CA, Davidovits A, Raab I, Jahn R, Ashour O, Spitzauer S, Sunder-Plassmann G, Fukuda M, Klemm P, Rees AJ, Kerjaschki D. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008; 14: 1088-1096
7. Knight A, Sandin S, Askling J. Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease. Arthritis Rheum 2008; 58: 302-307
8. Willcocks LC, Lyons PA, Rees AJ, Smith KG. The contribution of genetic variation and infection to the pathogenesis of ANCA-Associated systemic vasculitis. Arthritis Res Ther 2010; 12: 202
9. Segelmark M, Elzouki AN, Wieslander J, Eriksson S. The PiZ gene of alpha 1-Antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. Kidney Int 1995; 48: 844-850
10. Carr EJ, Niederer HA, Williams J, Harper L, Watts RA, Lyons PA, Smith KG. Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-Associated vasculitis. BMC Med Genet 2009; 10: 121
11. Jagiello P, Aries P, Arning L, Wagenleiter SE, Csernok E, Hellmich B, Gross WL, Epplen JT. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum 2005; 52: 4039-4043
12. Martorana D, Maritati F, Malerba G, Bonatti F, Alberici F, Oliva E, Sebastio P, Manenti L, Brugnano R, Catanoso MG, Fraticelli P, Guida G, Gregorini G, Possenti S, Moroni G, Leoni A, Pavone L, Pesci A, Sinico RA, Di Toma L, D'Amico M, Tumiati B, D'Ippolito R, Buzio C, Neri TM, Vaglio A. PTPN22 R620W polymorphism in the ANCA-Associated vasculitides. Rheumatology (Oxford) 2012; 51: 805-812
13. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hruskova Z, Little MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesar V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton DG, Smith KG. Genetically distinct subsets within ANCA-Associated vasculitis. N Engl J Med 2012; 367: 214-223
14. Botto M, Fong KY, So AK, Koch C, Walport MJ. Molecular basis of polymorphisms of human complement component C3. J Exp Med 1990; 172: 1011-1017
15. van der Pol W, van de Winkel JG. IgG receptor polymorphisms: risk factors for disease. Immunogenetics 1998; 48: 222-232
16. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998; 28: 2598-2602
17. Persson U, Truedsson L, Westman KW, Segelmark M. C3 and C4 allotypes in anti-neutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis. Clin Exp Immunol 1999; 116: 379-382
18. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D. Development and validation of a consensus methodology for the classification of the ANCAassociated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66: 222-227
19. Nässberger L, Truedsson L, Svantesson H. Occurrence of autoantibodies against neutrophil granulocyte components in juvenile chronic arthritis. Clin Exp Rheumatol 1991; 9: 79-83
20. Bygren P, Rasmussen N, Isaksson B, Wieslander J. Anti-neutrophil cytoplasm antibodies, anti-GBM antibodies and anti-dsDNA antibodies in glomerulonephritis. Eur J Clin Invest 1992; 22: 783-792
21. Huang D, Liu L, Noren K, Xia SQ, Trifunovic J, Pirskanen R, Lefvert AK. Genetic association of CTLA-4 to myasthenia gravis with thymoma. J Neuroimmunol 1998; 88: 192-198
22. Weber JL, May PE. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet 1989; 44: 388-396
23. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 1995; 80: 41-45
24. Zauner I, Bohler J, Braun N, Grupp C, Heering P, Schollmeyer P. Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS). Nephrol Dial Transplant 1994; 9: 619-622
25. Blakemore AI, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1380-1385
26. Finn JE, Zhang L, Agrawal S, Jayne DR, Oliveira DB, Mathieson PW. Molecular analysis of C3 allotypes in patients with systemic vasculitis. Nephrol Dial Transplant 1994; 9: 1564-1567
27. Huang D, Giscombe R, Zhou Y, Lefvert AK. Polymorphisms in CTLA-4 but not tumor necrosis factor-Alpha or interleukin 1beta genes are associated with Wegener's granulomatosis. J Rheumatol 2000; 27: 397-401
28. Gou SJ, Yuan J, Chen M, Yu F, Zhao MH. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-Associated vasculitis. Kidney Int 2013; 83: 129-137
29. Rambausek M, van den Wall Bake AW, Schumacher-Ach R, Spitzenberg R, Rother U, van Es LA, Ritz E. Genetic polymorphism of C3 and Bf in IgA nephropathy. Nephrol Dial Transplant 1987; 2: 208-211
30. Finn JE, Mathieson PW. Molecular analysis of C3 allotypes in patients with nephritic factor. Clin Exp Immunol 1993; 91: 410-414
31. Schwertz R, Rother U, Anders D, Gretz N, Scharer K, Kirschfink M. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-Term follow-up. Pediatr Allergy Immunol 2001; 12: 166-172
32. Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, Clayton DG, Hayward C, Morgan J, Wright AF, Armbrecht AM, Dhillon B, Deary IJ, Redmond E, Bird AC, Moore AT. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007; 357: 553-561
33. Steiner K, Moosig F, Csernok E, Selleng K, Gross WL, Fleischer B, Broker BM. Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis. Clin Exp Immunol 2001; 126: 143-150
34. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-1915
35. Lee YH, Choi SJ, Ji JD, Song GG. CTLA-4 and TNF-Alpha promoter-308 A/G polymorphisms and ANCAassociated vasculitis susceptibility: a meta-Analysis. Mol Biol Rep 2012; 39: 319-326
36. Huang D, Giscombe R, Zhou Y, Pirskanen R, Lefvert AK. Dinucleotide repeat expansion in the CTLA-4 gene leads to T cell hyper-reactivity via the CD28 pathway in myasthenia gravis. J Neuroimmunol 2000; 105: 69-77